Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Scandinavian Journal of Clinical and Laboratory Investigation
|
February 1, 1997
Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA
C Fledelius, I Kolding, P Qvist, et al.
Osteoarthritis and Cartilage
|
May 16, 2006
Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?
M A Karsdal, L B Tanko, B J Riis, et al.
Assay and Drug Development Technologies
|
November 25, 2005
In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?
S Schaller, K Henriksen, P Hoegh-Andersen, et al.
Osteoarthritis and Cartilage
|
September 26, 2006
MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays
E U Sumer, B C Sondergaard, J C Rousseau, et al.
Osteoarthritis and Cartilage
|
March 28, 2006
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation
B C Sondergaard, K Henriksen, H Wulf, et al.
Osteoarthritis and Cartilage
|
October 19, 2006
Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen
A K Olsen, B C Sondergaard, I Byrjalsen, et al.
Osteoarthritis and Cartilage
|
March 22, 2006
Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes
B C Sondergaard, H Wulf, K Henriksen, et al.
Calcified Tissue International
|
February 13, 2004
Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT
H N Rosen, R A Parker, S L Greenspan, et al.
Bone
|
June 18, 2003
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens
L B Tankó, U Mouritzen, H J Lehmann, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 8, 2003
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation
P Garnero, M Ferreras, M A Karsdal, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Scandinavian Journal of Clinical and Laboratory Investigation
|
February 1, 1997
Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA
C Fledelius, I Kolding, P Qvist, et al.
Osteoarthritis and Cartilage
|
May 16, 2006
Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?
M A Karsdal, L B Tanko, B J Riis, et al.
Assay and Drug Development Technologies
|
November 25, 2005
In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?
S Schaller, K Henriksen, P Hoegh-Andersen, et al.
Osteoarthritis and Cartilage
|
September 26, 2006
MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays
E U Sumer, B C Sondergaard, J C Rousseau, et al.
Osteoarthritis and Cartilage
|
March 28, 2006
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation
B C Sondergaard, K Henriksen, H Wulf, et al.
Osteoarthritis and Cartilage
|
October 19, 2006
Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen
A K Olsen, B C Sondergaard, I Byrjalsen, et al.
Osteoarthritis and Cartilage
|
March 22, 2006
Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes
B C Sondergaard, H Wulf, K Henriksen, et al.
Calcified Tissue International
|
February 13, 2004
Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT
H N Rosen, R A Parker, S L Greenspan, et al.
Bone
|
June 18, 2003
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens
L B Tankó, U Mouritzen, H J Lehmann, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 8, 2003
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation
P Garnero, M Ferreras, M A Karsdal, et al.
Page
of 6